Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Cardiac (Paediatric)
  6. Alfentanil and Remifentanil Weaning in Ventilated Post-operative Cardiac Patients in PICU, Paediatrics (388)
March 2025 newsletter now available - see below.

Welcome to the March 2025 update from the RDS team

1.     RDS issues - resolutions

1.1 Stability issues - Tactuum implemented a fix on 24th March which we believe has finally addressed the stability issues experienced over recent weeks.  The issue seems to have been related to the new “Tool export” function making repeated calls for content when new toolkit nodes were opened in Umbraco. No outages have been reported since then, and no performance issues in the logs, so fingers crossed this is now resolved.

1.2 Toolkit URL redirects failing– these were restored manually for the antimicrobial calculators on the 13th March when the issue occurred, and by 15th March for the remainder. The root cause was traced to adding a new hostname for an app migrated from another health board and made live that day. This led to the content management system automatically creating internal duplicate redirects, reaching the maximum number of permitted redirects and most redirects therefore ceasing to function.

This issue should not happen again because:

  • All old apps are now fully migrated to RDS. The large number of migrations has contributed to the high number of automated redirects.
  • If there is any need to change hostnames in future, Tactuum will immediately check for duplicates.

1.3 Gentamicin calculators – Incidents have been reported incidents of people accessing the wrong gentamicin calculator for their health board.  This occurs when clinicians are searching for the gentamicin calculator via an online search engine - e.g. Google - rather than via the health board directed policy route. When accessed via an external search engine, the calculator results are not listed by health board, and the start page for the calculator does not make it clearly visible which health board calculator has been selected.

The Scottish Antimicrobial Prescribing Group has asked health boards to provide targeted communication and education to ensure that clinicians know how to access their health board antimicrobial calculators via the RDS, local Intranet or other local policy route. In terms of RDS amendments, it is not currently possible to change the internet search output, so the following changes are now in progress:

  • The health board name will now be displayed within the calculator and it will be made clear which boards are using the ‘Hartford’ (7mg/kg) higher dose calculator
  • Warning text will be added to the calculator to advise that more than one calculator is in use in NHS Scotland and that clinicians should ensure they access the correct one for their health board. A link to the Right Decision Service list of health board antimicrobial prescribing toolkits will be included with the warning text. Users can then access the correct calculator for their Board via the appropriate toolkit.

We would encourage all editors and users to use the Help and Support standard operating procedure and the Editors’ Teams channel to highlight issues, even if you think they may be temporary or already noted. This helps the RDS team to get a full picture of concerns and issues across the service.

 

2.     New RDS presentation – RDS supporting the patient journey

A new presentation illustrating how RDS supports all partners in the patient journey – multiple disciplines across secondary, primary, community and social care settings – as well as patients and carers through self-management and shared decision-making tools – is now available. You will find it in the Promotion and presentation resources for editors section of the Learning and support toolkit.

3.     User guides

A new user guide is now available in the Guidance and tips section of Resources for providers within the Learning and Support area, explaining how to embed content from Google Calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream and Jotforms into RDS pages. A webinar for editors on using this new functionality is scheduled for 1 May 3-4 pm (booking information below.)

A new checklist to support editors in making all the checks required before making a new toolkit live is now available at the foot of the “Request a new toolkit” standard operating procedure. Completing this checklist is not a mandatory part of the governance process, but we would encourage you to use it to make sure all the critical issues are covered at point of launch – including organisational tags, use of Alias URLs and editorial information.

4.Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Tuesday 29th April 4-5 pm
  • Thursday 1st May 4-5 pm

Special webinar for RDS editors – 1 May 3-4 pm

This webinar will cover:

  1. a) Use of the new left hand navigation option for RDS toolkits.
  2. b) Integration into RDS pages of content from external sources, including Google Calendar, Google Maps and simple Jotforms calculators.

Running usage statistics reports using Google analytics

  • Wednesday 23rd April 2pm-3pm
  • Thursday 22nd May 2pm-3pm

To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

5.New RDS toolkits

The following toolkits were launched during March 2025:

SIGN guideline - Prevention and remission of type 2 diabetes

Valproate – easy read version for people with learning disabilities (Scottish Government Medicines Division)

Obstetrics and gynaecology induction toolkit (NHS Lothian) – password-protected, in pilot stage.

Oral care for care home and care at home services (Public Health Scotland)

Postural care in care homes (NHS Lothian)

Quit Your Way Pregnancy Service (NHS GGC)

 

6.New RDS developments

Release of the redesign of RDS search and browse, archiving and version control functionality, and editing capability for shared content, is now provisionally scheduled for early June.

The Scottish Government Realistic Medicine Policy team is leading development of a national approach to implementation of Patient-Reported Outcome Measures (PROMs) as a key objective within the Value Based Health and Care Action Plan. The Right Decision Service has been commissioned to deliver an initial version of a platform for issuing PROMs questionnaires to patients, making the PROMs reports available from patient record systems, and providing an analytics dashboard to compare outcomes across services.  This work is now underway and we will keep you updated on progress.

The RDS team has supported Scottish Government Effective Prescribing and Therapeutics Division, in partnership with Northern Ireland and Republic of Ireland, in a successful bid for EU funding to test develop, implement and assess new integrated care pathways for polypharmacy, including pharmacogenomics. As part of this project, the RDS will be working with NHS Tayside to test extending the current polypharmacy RDS decision support in the Vision primary care electronic health record system to include pharmacogenomics decision support.

7. Implementation projects

We have just completed a series of three workshops consulting on proposed improvements to the Being a partner in my care: Realistic Medicine together app, following piloting on 10 sites in late 2024. This app has been commissioned by Scottish Government Realistic Medicine to support patients and citizens to become active partners in shared decision-making and encouraging personalised care based on outcomes that matter to the person. We are keen to gather more feedback on this app. Please forward any feedback to ann.wales3@nhs.scot

 

 

Alfentanil and Remifentanil Weaning in Ventilated Post-operative Cardiac Patients in PICU (388)

Warning

Objectives

Cardiac patients in PICU: weaning Alfentanil and Remifentanil in ventilated post-operative cardiac patients in PICU.

This guideline has been written to standardise the smooth transition of alfentanil/remifentanil to morphine in PICU.

Scope

This aide-memoire is specifically for intubated, ventilated children in PICU during the first few hours post-cardiac surgery. It is intended for children with an Alfentanil or a Remifentanil infusion which has been started in theatre and which is still running when the child arrives in PICU. It is aimed at nursing and medical staff in PICU.

Summary

It is proposed to standardise the weaning of either Alfentanil or Remifentanil by:

1) Loading with Morphine,

2) Establishing a Morphine infusion and

3) Continuing the Remifentanil or Alfentanil infusion for at least 2 hours before stopping.

Algorithm

 

Ventilated patient returns to PICU with Remifentanill ir Alfentanil infusion running flowchart

Methodology

There is no published literature as such looking at transitioning between opiods in PICU. This suggested pathway is thus taken from current practice, expert opinion from within anaesthetics and intensive care and knowledge of the pharmacokinetics of the drugs involved. The pathway has been subjected to review within anaesthetics and PICU and comments and feedback have been incorporated.

Pharmacology

Classically Morphine was the opiate of choice in cardiac anaesthesia. A total dose of 1mg/kg was used, divided into four equal doses, 0.25mg/kg in the anaesthetic room, 0.25mg/kg prior to sternotomy, 0.25mg/kg  going onto bypass and 0.25mg/kg during rewarming. Morphine’s slow onset and long half-life (t½) has led to newer opiods being used intra-operatively. 

Alfentanil and Remifentanil are potent opiod analgesics with rapid onset and clearance when compared to Morphine. They are used as infusions in theatre and in the immediate post-operative period. The analgesic actions of Alfentanil and Remifentanil modify the haemodynamic responses to surgical stress. Both are potent mu agonists with the characteristic side effects of all opiods, including profound respiratory depression. Their rapid offset can leave the patient in pain post-operatively. 

Following cardiac surgery there will be an ongoing need for analgesia. Patients in PICU on conventional ventilation would normally be loaded with Morphine prior to the discontinuation of Alfentanil or Remifentanil.

Morphine

Induction of Analgesia: 0.1 – 0.2 mg/kg. (Cardiac anaesthesia up to 1mg/kg in divided doses)

Maintenance of Analgesia by continuous infusion: 10 - 30ug/kg/hr

Continuation infusion in PICU: 10-40ug/kg/hr

Following IV bolus administration the onset time of Morphine is relatively slow taking 15-30 minutes. Morphine has a low lipid solubility (about 2.5% that of fentanyl) and at physiological pH is 80% ionized, which slows passage through the blood brain barrier. Its offset is also slower with a t½ of some 2 hours. One of its major metabolites morphine-6-glucoronide has virtually identical actions to morphine and an even longer t½. 

Alfentanil

Induction of Analgesia: 50-75 mcg/kg (Loading doses typically given in theatre over several minutes or as 10ug/kg increments)

Maintenance of Analgesia by Continuous Infusion: 0.5 to 3 mcg/kg/min

Continuation infusion in PICU0.5 – 4 ug/kg/min

The pharmacokinetics of Alfentanil can be described as a three-compartment model with initial distribution t½ of 1 and 14 minutes; and a terminal elimination t½ of 90-111 minutes.

After a short intra-operative infusion the effective clinical half life of Alfentanil will be that of the phase 1 and 2 redistribution phases but after an infusion of a few hours it’s half life will be more dependant on the terminal elimination phase (fig.1).

Remifentanil

Induction of Analgesia: 1 mcg/kg (Loading doses typically given in theatre over several minutes or as 0.1ug/kg increments)

Maintenance of Analgesia by Continuous Infusion: 0.1 to 4 mcg/kg/min (Average rate 1 to 1.5 mcg/kg/min)

Continuation infusion in PICU0.5- 1mcg/kg/min

The analgesic effects of Remifentanil are rapid in onset and offset. Remifentanil is an esterase metabolised opioid. A labile ester linkage renders this compound susceptible to hydrolysis by nonspecific esterases in blood and tissues. This gives Remifentanil an effective t½ of approximately 3 to 6 minutes. Due to the rapid offset of action of Remifentanil, no residual analgesic activity will be present within 5 to 10 minutes after discontinuation. This is irrespective of the duration of the infusion (fig.1). For this reason Remifentanil is rarely used for cardiac patients.

Fig 1.

For patients undergoing surgical procedures where postoperative pain is generally anticipated, alternative analgesics should be administered prior to discontinuation of Alfentanil or Remifentanil. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of follow-up care.

Pharmacokinetics

It takes 3.3 half lives of a drug infusion to reach 90% of steady state concentration and 5 half lives to reach 97% of the final steady state concentration. In morphine’s case this would take some 6-10 hours. The use of a bolus dose allows the steady state to be reached more quickly as the infusion then merely has to maintain the drug concentration rather than building to a steady state (fig 2).

Fig 2

Recommendation

When using a combined Alfentanil/Morphine technique the anaesthetist will usually load the patient with a dose of Morphine in the period between rewarming and returning the patient to PICU, titrating the Morphine dose to the patient’s response.It is essential to ascertain from the anaesthetist whether a loading dose of morphine has been administered in theatre prior to the patient being transferred to PICU. This should be clearly documented on the handover form from theatre.

If the patient has received a loading dose of Morphine in theatre then they can be started on a morphine infusion on return to PICU as per normal indications at 10- 40ug/kg/hr of Morphine to keep the patient comfortable and to maintain light sedation (comfort score of 17-25).

If the patient has not received a loading dose of Morphine in theatre then a dose of 0.1mg/kg (0.05mg/kg in neonates) should be given at the start of the Morphine infusion. Further boluses of morphine can be administered as per standard practice from the syringe pump 1-2ml bolus (0.02 -0.04 mg/kg) if required.

If an Alfentanil or Remifentanil infusion is running from theatre the infusion should not be stopped immediately on arrival in PICU.

To allow a smooth transition from an Alfentanil/ Remifentanil infusion to a morphine infusion the Alfentanil/ Remifentanil infusion should be carried on at a rate of 0.5ug/kg/min ideally for at least 2hrs ( i.e. 1 morphine t½ ) to allow the morphine to reach a steady state. If there is less than 2 hours of Alfentanil/ Remifentanil in the pump then we can anticipate that additional morphine boluses will be required to allow an effective steady state of Morphine to be achieved more rapidly. A dose of 0.5ug/kg/min is suggested for both Alfentanil and Remifentanil for simplicity but it should be noted that this is a low dose of Alfentanil and a moderate dose of Remifentanil. 

Editorial Information

Last reviewed: 31/10/2017

Next review date: 11/08/2021

Author(s): Neil Spenceley.

Approved By: Paediatric Clinical Effectiveness & Risk Committee

Reviewer name(s): Colin Begg.

Document Id: 388

References

1. Egan, TD (1997). Remifentanil: an esterase-metabolized opioid. West J Med. 166(3): 202

2. Frank Shann (2014). Drug Doses 16th Edition via the Royal Children's Hospital Melbourne Clinical Practice Guidelines website.

3. BNF for Children: Ch4, Section 4: Pain; Opioids & Ch15, Section 1.6: Perioperative Analgesia; Opioids.

4. Birkett, DJ (2010). Pharmacodynamics made Easy. McGraw-Hill Education. (Based on a series of articles from Australian Prescriber, 1996).